Xeris Biopharma Holdings: Innovating Therapeutics to Enhance Patient Care and Outcomes

Xeris Biopharma Holdings: Pioneering Innovative Therapeutics for Patient Care

Xeris Biopharma Holdings, Inc., a biopharmaceutical company based in Chicago, is committed to enhancing patient care through the development of innovative therapeutic products. With a focus on rare and chronic conditions, Xeris has established itself in the healthcare landscape by marketing three key products: Recorlev®, Gvoke®, and Keveyis®. Recorlev® addresses endogenous Cushing’s syndrome, a hormonal disorder that can have severe health implications. Gvoke® is a ready-to-use liquid glucagon designed for the rapid treatment of severe hypoglycemia, while Keveyis® is utilized for primary periodic paralysis, a rare neuromuscular disorder. By targeting these specific medical needs, Xeris aims to improve patient outcomes significantly.

The company is not only focused on its current product lineup but is also advancing a robust pipeline of development programs. These initiatives leverage Xeris' proprietary formulation technologies, XeriSol® and XeriJect®, which facilitate the long-term development of new therapeutics. This strategy is vital as it positions Xeris to expand its offerings while ensuring the commercial viability of its products. The emphasis on proprietary technologies underscores the company's commitment to innovation and highlights its potential to address unmet medical needs in various therapeutic areas.

Xeris Biopharma's dedication to enhancing patient care is further reflected in its active engagement with the investment community. Recently, the company announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for December 3, 2024. This fireside chat provides an opportunity for senior management to discuss the company's vision and advancements directly with investors and stakeholders. The event will be accessible through a live webcast, allowing a broad audience to connect with Xeris' initiatives and future plans.

In addition to its product offerings and development pipeline, Xeris maintains an informative online presence. Interested parties can find detailed information about their initiatives and products on the company’s website, as well as on various social media platforms, including X, LinkedIn, and Instagram. This outreach not only keeps stakeholders informed but also fosters a community around the company's mission to improve patient care through innovation.

As Xeris Biopharma continues to evolve, it remains focused on its goal of developing therapies that address critical healthcare needs, reinforcing its position as a leader in the biopharmaceutical industry.